<DOC>
	<DOCNO>NCT00002600</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Bone marrow transplantation peripheral stem cell transplantation may allow doctor give high dos chemotherapy kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy carboplatin cyclophosphamide follow bone marrow peripheral stem cell transplantation treat patient advanced ovarian epithelial cancer .</brief_summary>
	<brief_title>Combination Chemotherapy , Bone Marrow Transplantation , Peripheral Stem Cell Transplantation Treating Patients With Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose carboplatin combine cyclophosphamide high-dose therapy follow autologous bone marrow peripheral blood stem cell rescue patient platinum sensitive ovarian epithelial carcinoma . II . Determine efficacy regimen patient . OUTLINE : This dose escalation study carboplatin . Autologous bone marrow ( ABM ) harvest day -11 , filgrastim ( G-CSF ) administer subcutaneously ( SC ) day -11 -7 , autologous peripheral blood stem cell ( PBSC ) harvest day -6 . Patients receive high dose chemotherapy comprise carboplatin IV 15 minute day -5 -4 cyclophosphamide IV 1 hour day -3 -2 . PBSC reinfused day -1 , ABM reinfused day 0 , G-CSF administer SC begin day 7 continue blood count recover . Cohorts 2-4 patient receive escalate dos carboplatin maximum tolerate dose ( MTD ) determine . The MTD define dose 10 % patient experience dose-limiting toxicity . A minimum 6 patient receive carboplatin MTD . Patients follow 1 month every 3 month 5 year . PROJECTED ACCRUAL : A minimum 18 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced ovarian epithelial malignancy one follow histology : Serous adenocarcinoma Endometrioid adenocarcinoma Mucinous adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial carcinoma Fallopian tube extraovarian peritoneal papillary serous tumor also allow Documented responsiveness ( use establish clinical criterion ) platinumbased chemotherapy regimen require Partial complete clinical response recent chemotherapy regimen require Bone marrow aspirate biopsy morphologically negative carcinoma cellularity great 50 % No CNS involvement PATIENT CHARACTERISTICS : Age : 18 65 Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL* SGOT le 60 IU/mL* * Unless abnormality due metastatic involvement Renal : Creatinine le 2.0 mg/dL* * Unless abnormality due metastatic involvement Cardiovascular : LVEF least 45 % MUGA scan No active congestive heart failure No myocardial infarction within past year No active arrhythmia No active angina pectoris No uncontrolled hypertension Pulmonary : FVC FEV least 50 % predict Other : No peripheral neuropathy No uncontrolled diabetes mellitus No history malignancy except basal cell squamous cell skin cancer No debilitate medical psychiatric illness would preclude informed consent study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 2 prior chemotherapy regimen At least 4 week since prior chemotherapy ( least 6 week since prior nitrosoureas ) Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy ovarian cancer Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2001</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>